References
- 1. Antwi-Boasiako C, Frimpong E, Gyan B, et al. Elevated proangiogenic markers are associated with vascular complications within ghanaian sickle cell disease patients. Medical sciences. 2018; 6.10.3390/medsci6030053616408529954157
- 2. Conran N, Almeida CB. Hemolytic vascular inflammation: An update. Revista brasileira de hematologia e hemoterapia. 2016; 38: 55–57.10.1016/j.bjhh.2015.10.004478676426969775
- 3. Kato GJ, Hebbel RP, Steinberg MH, et al. Vasculopathy in sickle cell disease: Biology, patho-physiology, genetics, translational medicine, and new research directions. American journal of hematology. 2009; 84: 618–625.10.1002/ajh.21475320971519610078
- 4. Usmani A, Machado RF. Vascular complications of sickle cell disease. Clinical hemorheology and microcirculation. 2018;68:205-22110.3233/CH-189008719447529614633
- 5. Castro O, Hoque M, Brown BD. Pulmonary hypertension in sickle cell disease: Cardiac catheterization results and survival. Blood. 2003;101:1257-126110.1182/blood-2002-03-094812393669
- 6. Heller PG, Grinberg AR, Lencioni M, et al. Pulmonary hypertension in paroxysmal nocturnal hemoglobinuria. Chest. 1992; 102: 642–643.10.1378/chest.102.2.6421643968
- 7. Morris CR, Kuypers FA, Kato GJ, et al. Hemolysis-associated pulmonary hypertension in thalassemia. Annals of the New York Academy of Sciences. 2005; 1054: 481–485.10.1196/annals.1345.058321730016339702
- 8. Verresen D, De Backer W, Van Meerbeeck J, et al. Spherocytosis and pulmonary hypertension coincidental occurrence or causal relationship? The European respiratory journal. 1991; 4: 629–631.
- 9. Fonseca GH, Souza R, Salemi VM, et al. Pulmonary hypertension diagnosed by right heart catheterisation in sickle cell disease. The European respiratory journal. 2012; 39: 112–118.10.1183/09031936.0013441021778170
- 10. Mehari A, Gladwin MT, Tian X, et al. Mortality in adults with sickle cell disease and pulmonary hypertension. Jama. 2012; 307: 1254–1256.10.1001/jama.2012.358351104822453563
- 11. Parent F, Bachir D, Inamo J, et al. A hemodynamic study of pulmonary hypertension in sickle cell disease. The New England journal of medicine. 2011; 365: 44–53.10.1056/NEJMoa100556521732836
- 12. Derchi G, Galanello R, Bina P, et al. Prevalence and risk factors for pulmonary arterial hypertension in a large group of beta-thalassemia patients using right heart catheterization: A webthal study. Circulation. 2014; 129: 338–345.10.1161/CIRCULATIONAHA.113.00212424081970
- 13. Strange G, Playford D, Stewart S, et al. Pulmonary hypertension: Prevalence and mortality in the armadale echocardiography cohort. Heart. 2012; 98: 1805–1811.10.1136/heartjnl-2012-301992353338322760869
- 14. Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England journal of medicine. 2004; 350: 886–895.10.1056/NEJMoa03547714985486
- 15. Psatha N, Papayanni PG, Yannaki E. A new era for hemoglobinopathies: More than one curative option. Current gene therapy. 2017; 17: 364–378
- 16. Hsu LL, Champion HC, Campbell-Lee SA, et al. Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability. Blood. 2007;109:3088-309810.1182/blood-2006-08-039438185222417158223
- 17. Brittain EL, Janz DR, Austin ED et al. Elevation of plasma cell–free hemoglobin in pulmonary arterial hypertension. Chest. 2014; 146: 1478–1485.10.1378/chest.14-0809425161224945582
- 18. Taylor JGt, Nolan VG, Mendelsohn L, et al. Chronic hyper-hemolysis in sickle cell anemia: Association of vascular complications and mortality with less frequent vasoocclusive pain. PloS one. 2008; 3: e2095.10.1371/journal.pone.0002095233007018461136
- 19. Reiter CD, Wang X, Tanus-Santos JE, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nature medicine. 2002; 8: 1383–1389.10.1038/nm1202-79912426562
- 20. Morris CR, Kato GJ, Poljakovic M, et al. Dys-regulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. Jama. 2005; 294: 81–90.10.1001/jama.294.1.81206586115998894
- 21. James J, Srivastava A, Varghese MV, et al. Heme induces rapid endothelial barrier dysfunction via the mkk3/p38mapk axis. Blood. 2020;136:749-75410.1182/blood.2019003986741458932548640
- 22. Geiger JD PR, Nagy JI. Adenosine deaminase regulation of purine actions. In Adenosine and Adenine Nucleotides as Regulators of Cellular Function. Edited by Phillis JW, Coca Raton FL, CRC Press 1991: 71–84.
- 23. Sharff AJ, Wilson DK, Chang Z, et al. Refined 2.5 a structure of murine adenosine deaminase at ph 6.0. Journal of molecular biology. 1992; 226: 917–921.10.1016/0022-2836(92)91040-V
- 24. Tofovic SP, Jackson EK, Rafikova O. Adenosine deaminase-adenosine pathway in hemolysis-associated pulmonary hypertension. Medical hypotheses. 2009; 72: 713–719.10.1016/j.mehy.2008.12.04319237250
- 25. Tofovic SP, Kusaka H, Li P, et al. Effects of adenosine deaminase inhibition on blood pressure in old spontaneously hypertensive rats. Clinical and experimental hypertension. 1998;20:329-34410.3109/106419698090521259605386
- 26. Jackson EK, Koehler M, Mi Z, et al. Possible role of adenosine deaminase in vaso-occlusive diseases. Journal of hypertension. 1996;14:19-2910.1097/00004872-199601000-00003
- 27. Jackson EK, Mi Z, Koehler MT, et al. Injured erythrocytes release adenosine deaminase into the circulation. The Journal of pharmacology and experimental therapeutics. 1996; 279: 1250–1260.
- 28. Bilan VP, Schneider F, Novelli EM, et al. Experimental intravascular hemolysis induces hemodynamic and pathological pulmonary hypertension: Association with accelerated purine metabolism. Pulmonary circulation. 2018;8:2045894018791557.10.1177/2045894018791557608008430003836
- 29. Santos NC, Figueira-Coelho J, Martins-Silva J, et al. Multidisciplinary utilization of dimethyl sulfoxide: Pharmacological, cellular, and molecular aspects. Biochemical pharmacology. 2003; 65: 1035–1041.10.1016/S0006-2952(03)00002-9
- 30. DiStefano V, Klahn JJ. Observations on the pharmacology and hemolytic activity of dimethyl sulfoxide. Toxicology and applied pharmacology. 1965; 7: 660–666.10.1016/0041-008X(65)90122-55866804
- 31. Yi X, Liu M, Luo Q, et al. Toxic effects of dimethyl sulfoxide on red blood cells, platelets, and vascular endothelial cells in vitro. FEBS open bio. 2017; 7: 485–494.10.1002/2211-5463.12193537739628396834
- 32. Norred WP, Ansel HC, Roth IL, et al. Mechanism of dimethyl sulfoxide-induced hemolysis. Journal of pharmaceutical sciences. 1970; 59: 618–622.10.1002/jps.26005905095446416
- 33. Tofovic SP, Salah EM, Mady HH, et al. Estradiol metabolites attenuate monocrotaline-induced pulmonary hypertension in rats. Journal of cardiovascular pharmacology. 2005; 46: 430–437.10.1097/01.fjc.0000175878.32920.1716160593
- 34. Ren J, Mi Z, Jackson EK. Assessment of nerve stimulation-induced release of purines from mouse kidneys by tandem mass spectrometry. The Journal of pharmacology and experimental therapeutics. 2008; 325 :920–926.10.1124/jpet.108.13775218322147
- 35. MacArthur PH, Shiva S, Gladwin MT. Measurement of circulating nitrite and s-nitrosothiols by reductive chemiluminescence. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2007; 851: 93–105.10.1016/j.jchromb.2006.12.01217208057
- 36. Yang BK, Vivas EX, Reiter CD, et al. Methodologies for the sensitive and specific measurement of s-nitrosothiols, iron-nitrosyls, and nitrite in biological samples. Free radical research. 2003; 37: 1–10.10.1080/107157602100003311212653211
- 37. Morris SM, Jr., Kepka-Lenhart D, Chen LC. Differential regulation of arginases and inducible nitric oxide synthase in murine macrophage cells. The American journal of physiology. 1998;275:E740-74710.1152/ajpendo.1998.275.5.E7409814991
- 38. Ghosh S, Adisa OA, Chappa P, et al. Extracellular hemin crisis triggers acute chest syndrome in sickle mice. The Journal of clinical investigation. 2013; 123: 4809–4820.10.1172/JCI64578380977224084741
- 39. Wallace KL, Marshall MA, Ramos SI, et al. Nkt cells mediate pulmonary inflammation and dys-function in murine sickle cell disease through production of ifn-gamma and cxcr3 chemokines. Blood. 2009; 114: 667–676.10.1182/blood-2009-02-205492271346719433855
- 40. Kim R, Liu W, Chen X, et al. Intravesical dimethyl sulfoxide inhibits acute and chronic bladder inflammation in transgenic experimental autoimmune cystitis models. Journal of biomedicine & biotechnology. 2011; 2011: 937061.10.1155/2011/937061298938321113298
- 41. Perez-Marrero R, Emerson LE, Feltis JT. A controlled study of dimethyl sulfoxide in interstitial cystitis. The Journal of urology. 1988;140:36-3910.1016/S0022-5347(17)41478-93288775
- 42. Tutolo M, Ammirati E, Castagna G, et al. A prospective randomized controlled multicentre trial comparing intravesical dmso and chondroitin sulphate 2% for painful bladder syndrome/interstitial cystitis. International braz j urol : official journal of the Brazilian Society of Urology. 2017; 43: 134–141.10.1590/s1677-5538.ibju.2016.0302
- 43. Dasgupta T, Hebbel RP, Kaul DK. Protective effect of arginine on oxidative stress in transgenic sickle mouse models. Free radical biology & medicine. 2006; 41: 1771–1780.10.1016/j.freeradbiomed.2006.08.025194897717157180
- 44. Morris CR, Morris SM, Jr., Hagar W, et al. Arginine therapy: A new treatment for pulmonary hypertension in sickle cell disease? American journal of respiratory and critical care medicine. 2003; 168: 63–69.
- 45. Spector EB, Rice SC, Kern RM, et al. Comparison of arginase activity in red blood cells of lower mammals, primates, and man: Evolution to high activity in primates. American journal of human genetics. 1985; 37: 1138–1145.
- 46. Tofovic SP BV, Gladwin M, Schneider F. Repetitive hemolysis induces severe angiopproloferative pulmonary hypertension in rats. 2012;. Am J Respir Crit Care Med. 2012; 185: A1247.10.1164/ajrccm-conference.2012.185.1_MeetingAbstracts.A1247
- 47. Tofovic SP EA, Jackson EK, Morris SM, Jr. 2-methoxyestradiol attenuates arginase induction and vascular remodeling in pulmonary hypertensive rats.. Proceed Am Thor Soc.. 2006;3 A856
- 48. Tofovic SP BV. Two rat models of hemolysis-induced pulmonary hypertension.. Eur Res J. 2010; 36: P107.
- 49. Khoury J, Ibla JC, Neish AS, et al. Antiinflammatory adaptation to hypoxia through adenosine-mediated cullin-1 deneddylation. The Journal of clinical investigation. 2007;117:703-71110.1172/JCI30049179760417318263
- 50. Xu MH, Gong YS, Su MS, et al. Absence of the adenosine a2a receptor confers pulmonary arterial hypertension and increased pulmonary vascular remodeling in mice. Journal of vascular research. 2011; 48: 171–183.10.1159/000316935297573620938208
- 51. Wallace KL, Linden J. Adenosine a2a receptors induced on inkt and nk cells reduce pulmonary inflammation and injury in mice with sickle cell disease. Blood. 2010; 116: 5010–5020.10.1182/blood-2010-06-290643301259420798237
- 52. Eltzschig HK, Ibla JC, Furuta GT, et al. Coordinated adenine nucleotide phosphohydrolysis and nucleoside signaling in posthypoxic endothelium: Role of ectonucleotidases and adenosine a2b receptors. The Journal of experimental medicine. 2003; 198: 783–796.10.1084/jem.20030891219418912939345
- 53. Thompson LF, Eltzschig HK, Ibla JC, et al. Crucial role for ecto-5’-nucleotidase (cd73) in vascular leakage during hypoxia. The Journal of experimental medicine. 2004; 200: 1395–140510.1084/jem.20040915123701215583013
- 54. Saadjian AY, Paganelli F, Gaubert ML, et al. Adenosine plasma concentration in pulmonary hypertension. Cardiovascular research. 1999; 43: 228–236.10.1016/S0008-6363(99)00059-010536708
- 55. Saadjian AY, Paganelli F, Juin MA, et al. Plasma beta-endorphin and adenosine concentration in pulmonary hypertension. The American journal of cardiology. 2000; 85: 858–863.10.1016/S0002-9149(99)00881-410758927
- 56. Fullerton DA, Jaggers J, Jones SD, et al. Adenosine for refractory pulmonary hypertension. The Annals of thoracic surgery. 1996; 62: 874–877.10.1016/S0003-4975(96)00361-X
- 57. Fullerton DA, Jones SD, Grover FL, et al. Adenosine effectively controls pulmonary hypertension after cardiac operations. The Annals of thoracic surgery. 1996; 61: 1118–1123; discussion 1123–1114.10.1016/0003-4975(95)01149-88607668
- 58. Motti A, Tissot C, Rimensberger PC, et al. Intravenous adenosine for refractory pulmonary hypertension in a low-weight premature newborn: A potential new drug for rescue therapy. Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies. 2006; 7: 380–382.10.1097/01.PCC.0000225000.78627.EB16738499
- 59. Ng C, Franklin O, Vaidya M, et al. Adenosine infusion for the management of persistent pulmonary hypertension of the newborn. Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies. 2004; 5: 10–13.10.1097/01.CCM.0000105309.27519.2714697102
- 60. Canpolat F, Unver M, Eskioglu F, et al. Serum and erythrocyte adenosine deaminase activities in patients with behcet’s disease. International journal of dermatology. 2006; 45: 1053–1056.10.1111/j.1365-4632.2006.02892.x16961545
- 61. Erkilic K, Evereklioglu C, Cekmen M, et al. Adenosine deaminase enzyme activity is increased and negatively correlates with catalase, super-oxide dismutase and glutathione peroxidase in patients with behcet’s disease: Original contributions/clinical and laboratory investigations. Mediators of inflammation. 2003; 12: 107–116.10.1080/0962935031000097754178159812775361
- 62. Cowan MJ, Brady RO, Widder KJ. Elevated erythrocyte adenosine deaminase activity in patients with acquired immunodeficiency syndrome. Proceedings of the National Academy of Sciences of the United States of America. 1986; 83: 1089–1091.10.1073/pnas.83.4.10893230163006027
- 63. Khodadadi I, Abdi M, Ahmadi A, et al. Analysis of serum adenosine deaminase (ada) and ada1 and ada2 isoenzyme activities in hiv positive and hiv-hbv co-infected patients. Clinical biochemistry. 2011; 44: 980–983.10.1016/j.clinbiochem.2011.05.02021640091